Ozagrel (sodium)

Ozagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2) . Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases[1][2][3][4][5].

189224-26-8

OKY-046 (sodium)

12352005

Prostaglandin Receptor

Reference compound

GPCR/G Protein

COVID-19-immunoregulation

Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

https://www.medchemexpress.com/Ozagrel-sodium.html

99.82

DMSO : 6.25 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

O=C(O[Na])/C=C/C1=CC=C(CN2C=CN=C2)C=C1

C13H11N2NaO2

250.23

[1]Saito MS, et al. Antiplatelet pyrazolopyridines derivatives: pharmacological, biochemical and toxicological characterization. J Enzyme Inhib Med Chem. 2016 Dec;31 (6) :1591-601.|[2]Bhatia P, Singh N. Ameliorative effect of ozagrel, a thromboxane A2 synthase inhibitor, in hyperhomocysteinemia-induced experimental vascular cognitive impairment and dementia. Fundam Clin Pharmacol. 2021 Aug;35 (4) :650-666.|[3]Bhatia P, Kaur G, Singh N. Ozagrel a thromboxane A2 synthase inhibitor extenuates endothelial dysfunction, oxidative stress and neuroinflammation in rat model of bilateral common carotid artery occlusion induced vascular dementia. Vascul Pharmacol. 2021 Apr;137:106827.|[4]Nakazawa M, et al. [Research and development of ozagrel, a highly selective inhibitor of TXA2 synthase]. Yakugaku Zasshi. 1994;114 (12) :911-33.|[5]Ishitsuka Y, et al. A selective thromboxane A2 (TXA2) synthase inhibitor, ozagrel, attenuates lung injury and decreases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in oleic acid-induced lung injury in guinea pigs. J Pharmacol Sci. 2009 Oct;111 (2) :211-5.

Room Temperature

4°C (Powder, sealed storage, away from moisture)

Reference compound1

Launched